

**Procedures for Exporting Veterinary Pharmaceuticals that have  
received Initial Approval for Composition Statement Amendment  
Year 2026**

**Code: EDREX: NP.CAPP.079**

**Version No: 2**

**Issue Date: 8/4/2026**

**Procedures for Exporting Veterinary Pharmaceuticals that have received Initial Approval for Composition Statement Amendment, According to The Approval of The Chairman of The Egyptian Drug Authority Dated December 4, 2023**

- Regarding veterinary pharmaceuticals that have received initial approval for composition statement amendment, export may be permitted till completion of the variation requirements, provided that the following conditions are met:

1-Companies must submit a written undertaking, signed and stamped by the Chairman of the Board, stating that they bear full responsibility for all batches produced and intended for export only, and guaranteeing the safety, stability, and efficacy of the batches exported abroad. This applies if the company wishes to avoid implementing the variation requirements on these batches. This undertaking must be submitted to the Central administration of inspection on pharmaceutical institutions.

2-The phrase "For Export Only" must be clearly written on the packaging of batches intended for export, so that these batches are not permitted to be circulated locally.

3- The variation can be documented and added to the Export Certificates (CPP) issued by the Certification Department of the Central Administration of

**Central Administration for Pharmaceutical Products  
General Administration of Veterinary Pharmaceuticals**



Pharmaceutical Products, with the addition of a statement that it is not marketed in the country of origin until the company fulfills the variation requirements.